Skip to main content

The development of KRAS inhibitors has ushered in a new era in precision oncology and renewed efforts in therapeutic targeting of p53, the most commonly altered gene in human cancer. Cancer Research Catalyst took a deep dive in the latest developments, the status of clinical research, and the next frontiers for the field.

The post Cracking “Undruggable” Cancer Proteins: Precision Oncology Meets p53 appeared first on American Association for Cancer Research (AACR).

Source: Oncology

Read More